WebLaurikka-Routti. LKT, naistentautien ja synnytysten erikoislääkäri. Asiakasarvio 9.7. 24kk keskiarvo, kun vastauksia yli 25 kpl. Siirry verkkoajanvaraukseen. Marjut Laurikka … WebThe progest in ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be risk factors for coronary artery disease. Objective: To study the changes in serum lipids, serum chemistry, blood pressure, and body weight in long-term users of subcutaneous …
Contraception with subdermal implants releasing the
Web1 Nov 1992 · Laurikka-Routti M 1. Author information. Affiliations. 1 author. 1. City Maternity Hospital, Helsinki, Finland. Obstetrics and Gynecology, 01 Nov 1992, 80(5): 855-859 … Web1 Dec 1992 · M. Laurikka-Routti, M. Haukkamaa Published 1 December 1992 Medicine Fertility and sterility View on PubMed doi.org Save to Library Create Alert Cite 17 … sql server find field in database
Transdermal absorption of the progestin ST-1435 ... - Europe PMC
WebDOI: 10.1016/0010-7824(81)90115-3 Corpus ID: 72256207; Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435 Web1 Dec 1992 · Laurikka-Routti, M. Haukkamaa, O. Heikinheimo, A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipid and serum chemistry Contraception 42: (1990) 111-120 13. WebThese implants have been developed for contraception and they have a life-time of two years. Three implant lengths of 4, 6 and 8 cm were tested to find the optimal steroid dose … sql server find all indexes in database